Biogen, AbbVie drug slows MS episodes, safety issues recur | (Reuters) - A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future. | | | UK cost agency not ready to back Gilead hepatitis C drug | LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service. | | | | Bangladesh reports first case of MERS infection | DHAKA (Reuters) - Bangladesh on Sunday reported its first case of Middle East Respiratory Syndrome (MERS) coronavirus infection in a man returning from the United States through Abu Dhabi. | | | | | | | | The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today | | | | | | | A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today | | | | | » MORE NEWSLETTERS | |
No comments:
Post a Comment